[go: up one dir, main page]

WO1997003676A1 - Nouvelle formulation pharmaceutique de dehydroepiandrosterone pour application topique percutanee - Google Patents

Nouvelle formulation pharmaceutique de dehydroepiandrosterone pour application topique percutanee Download PDF

Info

Publication number
WO1997003676A1
WO1997003676A1 PCT/ES1996/000153 ES9600153W WO9703676A1 WO 1997003676 A1 WO1997003676 A1 WO 1997003676A1 ES 9600153 W ES9600153 W ES 9600153W WO 9703676 A1 WO9703676 A1 WO 9703676A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
dehydroepiandrosterone
glycolic
dhea
ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES1996/000153
Other languages
English (en)
Spanish (es)
Inventor
José CABO SOLER
Jesús CALDERON GOMEZ
Santiago PALACIOS GIL-ANTUÑANO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU64196/96A priority Critical patent/AU6419696A/en
Publication of WO1997003676A1 publication Critical patent/WO1997003676A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention falls within the technical field of hormonal therapy for the maintenance of certain vital functions that deteriorate with age or the treatment of various metabolic or degenerative diseases. More specifically, the present invention relates to a new form of presentation of dehydropediandrosterone (DHEA) intended for percutaneous topical application.
  • DHEA dehydropediandrosterone
  • DHEA Dehydroepiandrosterone
  • the present invention refers to a new pharmaceutical formulation of dehydroepiandrosterone intended for percutaneous topical application.
  • the applicant has been able to verify, after his investigations, that steroid hormones and, in particular, dehydroepiandrosterone are well absorbed topically, fundamentally, percutaneously. Therefore, as a result of this finding, the inventors propose a new form of pharmaceutical presentation of dehydroe ⁇ piandrosterone, as a gel, emulsion or solution intended for percutaneous application.
  • This type of application allows to reach, in blood, the most convenient levels for each problem (either replenish the physiological levels of other phases of life or raise them).
  • the formulation may comprise, in addition to ingredients (a) and (b) other hydrophilic gels, selected from glycolic, hydro-glycolic, hydroglycerolate, hydroalcoholic and hydropropylene glycol in similar proportions of 0.5-2% carbopol and other ingredients assets selected from 0.02-0.1% estradiol, 0.05-1% Vitamin E, 0.1-5% Vitamin C, 2-5% progesterone, 1-3% minoxidil, 0, 1-2% of tricosaccharides and tricopeptides, 0.1-5% of xanthic bases, 0.1-20% of iodinated products, 100-2000 U% of hyaluronidase, 0.1-12% of vasoprotective and capillary agents , 0.1-2% dinitrilesuccinic, 0.1-5% glycolic and hydroalcoholic extracts of capsicum and arnica, 0.1-0.75% camphor,
  • the formulation of the invention can be presented in any form suitable for percutaneous application, such as gel, emulsion, lotion, ointment, paste, dermal diffusion patch, etc.
  • the formulation is applied in a predetermined amount by rubbing over an area of the skin with good circulation (preferably the arms, forearms, abdomen, etc.) 1 to 3 times a day.
  • the optional active ingredients depend on the type of final utility that is intended to be given to the formulation.
  • DHEA In controlling the disorders of the female menstrual cycle and as a preventive of breast and gynecological malignancies, DHEA will be associated, in any of the ways described above, with estrogens (mainly estradiol, estrone and its derivatives) with a concentration of estradiol or equivalent of 0.02-0.1%. This neutralizes some of the negative effects of estrogen itself.
  • estrogens mainly estradiol, estrone and its derivatives
  • these preparations will be associated with Vitamin E (between 0.05 and 1%) and / or Vitamin C (between 0, one and 5%).
  • DHEA can be associated with Progesterone (between 2-5%) and / or with Minoxidil (between 1 and 3%), as well as with Tricosaccharides and tricopeptides (0.1-2%) for hair maintenance.
  • DHEA is associated with vasoprotective and capillary agents, both synthetic and naturally occurring (flavonoids, biflavonoids, anthocyanosides, procyanidoles and steroidal saponosides), especially glycolic and hydroalcocholic citrides (citrides) ) between 0.1-12%, the glycolic and alcoholic extracts of Ginko Biloba, between 0.1-15%, the glycolic and alcoholic extracts of Black and Red Currant, of Black Mirtilo and Red Vine between 0 , 1-15%.
  • DHEA can be associated with vesicant and rubefacient substances for topical therapies derived from congestion, hyperemias, bruises and muscle aches glycolic and hydroalcoholic extracts of capsicum and arnica between 0.1-5%; Camphor between 0.1-0.75%) and that of these substances with antipruritic substances (menthol, 0.01-0.5%, and glycolic and hydro-glycolic extract of Centella Asiatica, between 0.1-5% ).
  • DHEA can be associated with the natural (1-15%) or synthetic (0.1-5%) antiandrogens indicated above.
  • DHEA could be associated with any combination of the substances described in the previous sections.
  • This formulation can also be applied by dermal diffusion patches.
  • EXAMPLE 1 This Example illustrates various formulations according to the present invention, indicating the amounts of active ingredients used and the application to which they were intended: Formulation 1 DHEA 3%
  • Tricopeptides 1% This formulation is useful for the maintenance of axillary hair and hair as well as the treatment of certain forms of alopecia.
  • This formulation is useful for the treatment of congestion, hyperemias, bruises and muscle aches.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La nouvelle formulation comprend: (a) 0,1 à 5 % en poids de déhydroepiandrostérone; (b) 0,5-3 % d'un gel acrylique, 1-3 % de gomme guar ou 1-3 % d'un gel dérivé de cellulose; et, éventuellement, d'autres ingrédients tels que des gels hydrophiles, un estradiol, des vitamines, la progestérone, le minoxydile, des bases xantiques, une hyaluronidase, des vasoprotecteurs, des extraits de plantes, etc. La formulation a diverses applications pharmacologiques, par exemple pour le traitement de troubles de la menstruation chez la femme, des néoplasies mammaires et gynécologiques, des lipodystrophies, des paniculopathies et des troubles circulatoires, des contusions, des douleurs musculaires, l'obésité, le diabète, l'ostéoporose, le vieillissement, etc.
PCT/ES1996/000153 1995-07-21 1996-07-19 Nouvelle formulation pharmaceutique de dehydroepiandrosterone pour application topique percutanee Ceased WO1997003676A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64196/96A AU6419696A (en) 1995-07-21 1996-07-19 Novel pharmaceutical formulation of dehydroepiandrosterone for percutaneous topical application

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES9501471A ES2098193B1 (es) 1995-07-21 1995-07-21 Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
ESP9501471 1995-07-21

Publications (1)

Publication Number Publication Date
WO1997003676A1 true WO1997003676A1 (fr) 1997-02-06

Family

ID=8291123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES1996/000153 Ceased WO1997003676A1 (fr) 1995-07-21 1996-07-19 Nouvelle formulation pharmaceutique de dehydroepiandrosterone pour application topique percutanee

Country Status (3)

Country Link
AU (1) AU6419696A (fr)
ES (1) ES2098193B1 (fr)
WO (1) WO1997003676A1 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048502A1 (fr) * 1998-03-24 1999-09-30 Universidad Miguel Hernandez UTILISATION DU 17β ESTRADIOL, DE SES ANALOGUES ET DE SES DERIVES DANS LE TRAITEMENT DU DIABETE SUCRE ET SES MANIFESTATIONS
EP0963201A4 (fr) * 1996-07-12 2000-04-26 Carolyn V Shaak Application transdermique d'hormones stero diennes d'origine naturelle
WO1999063973A3 (fr) * 1998-06-11 2000-11-02 Endorech Inc COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS POUR L'ANDROST-5-ENE-3β,17β-DIOL
WO2001019365A1 (fr) * 1999-09-15 2001-03-22 Roche Consumer Health Ag Compositions pharmaceutiques et/ou cosmetiques
WO2001070258A1 (fr) * 2001-03-19 2001-09-27 Santana, Cristiano, Alberto, Ribeiro COMPOSITION PHARMACEUTIQUE POUR EXCIPIENT POUR PRODUITS A BASE DE VITAMINE E, DE BROMELINE ET D'HYALURONIDASE
EP1172094A1 (fr) * 2000-07-13 2002-01-16 L'oreal Composition, notamment cosmétique, comprenant la DHEA et/ou un précurseur ou dérivé, et au moins un composé augmentant la synthèse des glycosaminoglycanes
FR2811567A1 (fr) * 2000-07-13 2002-01-18 Oreal Composition, notamment cosmetique, comprenant la dhea et/ou un precurseur ou derive de celle-ci, en association avec au moins un inhibiteur de no-synthase
FR2811562A1 (fr) * 2000-07-13 2002-01-18 Oreal Composition, notamment cosmetique, renfermant la dhea et un isoflavonoide
WO2002034230A1 (fr) * 2000-10-26 2002-05-02 L'oreal Composition cosmetique renfermant la dhea et un agent anti-irritant
WO2002047647A1 (fr) * 2000-12-15 2002-06-20 L'oreal Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent depigmentant
WO2002047631A1 (fr) * 2000-12-15 2002-06-20 L'oreal Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoïde
WO2002047655A1 (fr) * 2000-12-15 2002-06-20 L'oreal Composition, notamment cosmetique, comprenant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un inhibiteur de no-synthase
FR2847475A1 (fr) * 2002-11-25 2004-05-28 Oreal COMPOSITION COSMETIQUE OU PHARMACEUTIQUE ASSOCIANT UN AGENT MODULATEUR DE L'EXPRESSION DE L'OXYSTEROL 7alpha-HYDROXYLASE ET UN SUBSTRAT BIOLOGIQUE DE LADITE ENZYME
EP1189619A4 (fr) * 1999-06-11 2004-06-09 Watson Pharmaceuticals Inc Administration de steroides androgenes non oraux aux femmes
WO2005102372A1 (fr) * 2004-04-26 2005-11-03 Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' Compositions de correction de changements du systeme endocrinien humain dus a l'age et procede de fabrication d'une forme pharmaceutique sur la base de ces compositions
US6994864B2 (en) 2000-12-15 2006-02-07 L'oreal Composition containing 7-hydroxy DHEA and/or 7-keto DHEA and at least a carotenoid
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US7354956B2 (en) 2002-04-12 2008-04-08 L'oreal Composition containing a sapogenin and use thereof
US7404965B2 (en) 2000-08-03 2008-07-29 Antares Pharma Ipl Ag Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US7442369B1 (en) 2000-08-09 2008-10-28 Mcneil Ab Compositions of minoxidil
EP1092423B1 (fr) * 1999-10-13 2009-05-13 L'oreal Utilisation de la DHEA ou de ses précurseurs ou dérivés métaboliques comme dépigmentant
US8268346B2 (en) 2006-04-21 2012-09-18 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8338400B2 (en) 2005-05-27 2012-12-25 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US8652491B2 (en) 2000-08-03 2014-02-18 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US8980309B2 (en) 2003-10-10 2015-03-17 Antares Pharma Ipl Ag Transdermal testosterone formulation for minimizing skin residues
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
US11324690B2 (en) 2019-02-12 2022-05-10 Dawn Marie Cutillo Composition for restorative vaginal lubrication and a method of use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350336B (es) 2011-12-29 2017-09-04 Univ Chile Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberacion del principio activo, util para aumentar la reserva ovarica en mujeres y para aliviar sintomas asociados a la menopausia.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60161912A (ja) * 1984-02-01 1985-08-23 Kanebo Ltd 皮膚化粧料
US4542129A (en) * 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
WO1994016709A2 (fr) * 1993-01-19 1994-08-04 Endorecherche Inc. Procedes therapeutiques et systemes d'apport de deshydroepiandrosterone

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542129A (en) * 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
JPS60161912A (ja) * 1984-02-01 1985-08-23 Kanebo Ltd 皮膚化粧料
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
WO1994016709A2 (fr) * 1993-01-19 1994-08-04 Endorecherche Inc. Procedes therapeutiques et systemes d'apport de deshydroepiandrosterone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 104, no. 2, 13 January 1986, Columbus, Ohio, US; abstract no. 10399s, KANEBO LTD.: "Cosmetics containing dehydroepiandrosterone" XP002018211 *

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0963201A4 (fr) * 1996-07-12 2000-04-26 Carolyn V Shaak Application transdermique d'hormones stero diennes d'origine naturelle
US6228852B1 (en) 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
WO1999048502A1 (fr) * 1998-03-24 1999-09-30 Universidad Miguel Hernandez UTILISATION DU 17β ESTRADIOL, DE SES ANALOGUES ET DE SES DERIVES DANS LE TRAITEMENT DU DIABETE SUCRE ET SES MANIFESTATIONS
US6884795B2 (en) 1998-06-11 2005-04-26 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
WO1999063973A3 (fr) * 1998-06-11 2000-11-02 Endorech Inc COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS POUR L'ANDROST-5-ENE-3β,17β-DIOL
US6432940B1 (en) 1998-06-11 2002-08-13 Endorecherche, Inc. Uses for androst-5-ene-3β, 17β-diol
US6995150B2 (en) 1998-06-11 2006-02-07 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
US6964955B2 (en) 1998-06-11 2005-11-15 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
US8551516B2 (en) 1999-06-11 2013-10-08 Actavis, Inc. Administration of non-oral androgenic steroids to women
EP1189619A4 (fr) * 1999-06-11 2004-06-09 Watson Pharmaceuticals Inc Administration de steroides androgenes non oraux aux femmes
CZ299198B6 (cs) * 1999-06-11 2008-05-14 Watson Pharmaceuticals, Inc. Souprava a lécivo pro zlepšování zdravotního stavu žen na bázi testosteronu
US7186706B2 (en) 1999-06-11 2007-03-06 Watson Pharmaceuticals, Inc. Administration of non-oral androgenic steroids to women
WO2001019365A1 (fr) * 1999-09-15 2001-03-22 Roche Consumer Health Ag Compositions pharmaceutiques et/ou cosmetiques
EP1092423B1 (fr) * 1999-10-13 2009-05-13 L'oreal Utilisation de la DHEA ou de ses précurseurs ou dérivés métaboliques comme dépigmentant
WO2002005778A1 (fr) * 2000-07-13 2002-01-24 L'oreal Composition, notamment cosmetique, comprenant la dhea et/ou un precurseur ou derive de celle-ci, en association avec au moins un inhibiteur de no-synthase
WO2002005764A1 (fr) * 2000-07-13 2002-01-24 L'oreal Composition, notamment cosmetique, renfermant la dhea et un isoflavonoïde
FR2811563A1 (fr) * 2000-07-13 2002-01-18 Oreal Composition, notamment cosmetique, comprenant la dhea et/ou un precurseur ou derive, et au moins un compose augmentant la synthese des glycosaminoglycanes
EP1172094A1 (fr) * 2000-07-13 2002-01-16 L'oreal Composition, notamment cosmétique, comprenant la DHEA et/ou un précurseur ou dérivé, et au moins un composé augmentant la synthèse des glycosaminoglycanes
FR2811567A1 (fr) * 2000-07-13 2002-01-18 Oreal Composition, notamment cosmetique, comprenant la dhea et/ou un precurseur ou derive de celle-ci, en association avec au moins un inhibiteur de no-synthase
FR2811562A1 (fr) * 2000-07-13 2002-01-18 Oreal Composition, notamment cosmetique, renfermant la dhea et un isoflavonoide
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US7404965B2 (en) 2000-08-03 2008-07-29 Antares Pharma Ipl Ag Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7470433B2 (en) 2000-08-03 2008-12-30 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US8652491B2 (en) 2000-08-03 2014-02-18 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7442369B1 (en) 2000-08-09 2008-10-28 Mcneil Ab Compositions of minoxidil
WO2002034230A1 (fr) * 2000-10-26 2002-05-02 L'oreal Composition cosmetique renfermant la dhea et un agent anti-irritant
FR2815858A1 (fr) * 2000-10-26 2002-05-03 Oreal Composition, notamment cosmetique, renfermant la dhea et/ou ses precurseurs ou derives, et un agent susceptible d'inhiber l'irritation d'origine neurogene
WO2002047647A1 (fr) * 2000-12-15 2002-06-20 L'oreal Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent depigmentant
FR2818136A1 (fr) * 2000-12-15 2002-06-21 Oreal Composition, notamment cosmetique, comprenant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un inhibiteur de no-synthase
US6994864B2 (en) 2000-12-15 2006-02-07 L'oreal Composition containing 7-hydroxy DHEA and/or 7-keto DHEA and at least a carotenoid
FR2818138A1 (fr) * 2000-12-15 2002-06-21 Oreal Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent depigmentant
FR2818148A1 (fr) * 2000-12-15 2002-06-21 Oreal Composition,notamment cosmetique, renfermant, la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoide
WO2002047631A1 (fr) * 2000-12-15 2002-06-20 L'oreal Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoïde
WO2002047655A1 (fr) * 2000-12-15 2002-06-20 L'oreal Composition, notamment cosmetique, comprenant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un inhibiteur de no-synthase
US6852326B2 (en) 2000-12-15 2005-02-08 L'oreal Composition, in particular cosmetic, containing 7-hydroxy DHEA and/or 7-keto DHEA and at least an isoflavonoid
WO2001070258A1 (fr) * 2001-03-19 2001-09-27 Santana, Cristiano, Alberto, Ribeiro COMPOSITION PHARMACEUTIQUE POUR EXCIPIENT POUR PRODUITS A BASE DE VITAMINE E, DE BROMELINE ET D'HYALURONIDASE
US7354956B2 (en) 2002-04-12 2008-04-08 L'oreal Composition containing a sapogenin and use thereof
FR2847475A1 (fr) * 2002-11-25 2004-05-28 Oreal COMPOSITION COSMETIQUE OU PHARMACEUTIQUE ASSOCIANT UN AGENT MODULATEUR DE L'EXPRESSION DE L'OXYSTEROL 7alpha-HYDROXYLASE ET UN SUBSTRAT BIOLOGIQUE DE LADITE ENZYME
US8980309B2 (en) 2003-10-10 2015-03-17 Antares Pharma Ipl Ag Transdermal testosterone formulation for minimizing skin residues
WO2005102372A1 (fr) * 2004-04-26 2005-11-03 Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' Compositions de correction de changements du systeme endocrinien humain dus a l'age et procede de fabrication d'une forme pharmaceutique sur la base de ces compositions
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US8338400B2 (en) 2005-05-27 2012-12-25 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US8268346B2 (en) 2006-04-21 2012-09-18 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8647665B2 (en) 2006-04-21 2014-02-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
US11324690B2 (en) 2019-02-12 2022-05-10 Dawn Marie Cutillo Composition for restorative vaginal lubrication and a method of use thereof

Also Published As

Publication number Publication date
ES2098193A1 (es) 1997-04-16
AU6419696A (en) 1997-02-18
ES2098193B1 (es) 1997-12-01

Similar Documents

Publication Publication Date Title
WO1997003676A1 (fr) Nouvelle formulation pharmaceutique de dehydroepiandrosterone pour application topique percutanee
ES2641280T3 (es) Método para aumentar el crecimiento del cabello
CN101897691B (zh) 异硫氰酸酯类化合物在促进毛发生长中的应用
CN111603505A (zh) 血管扩张剂制剂及使用方法
Sawaya et al. Androgenetic alopecia: new approved and unapproved treatments
KR20140107784A (ko) 탈모 방지 및 모발 성장 촉진용 조성물
US6403654B1 (en) Compositions for and method of treatment for psoriasis
ES2263682T3 (es) Tratamiento topico de la mastalgia.
US20040214750A1 (en) Medicaments for healing skin conditions in humans
KR20230074749A (ko) 모발, 두피 및 피부 트리트먼트 조성물
JP3596835B2 (ja) 養毛剤
KR102220534B1 (ko) 수딩 크림 및 이의 제조 방법
JP2005082600A (ja) 皮膚症状の治療方法
CN102441006B (zh) 一种含二氧化氯的生发溶液及其制备和使用方法
HU203668B (en) Cosmetic containing medicinal plants and process for producing composition against psoriasis
JPH0436221A (ja) 養毛料
US20050152993A1 (en) Composition for and method of treatment for skin ailments
WO2016144196A1 (fr) Composition pharmaceutique et/ou cosmétique pour traiter des lésions et maladies de peau, procédé de préparation de composition pharmaceutique et/ou cosmétique, et son utilisation
KR20010003366A (ko) 발모 및 육모제
KR101322850B1 (ko) 박하잎 추출물, 밀싹 추출물 및 길경 추출물을 유효성분으로 포함하는 모공 축소 또는 피지분비 억제용 화장료 조성물
KR20140041476A (ko) 바이러스 감염의 치료
CN102764416B (zh) 一种乌发制剂及制备方法
JPH0517202B2 (fr)
KR20020008268A (ko) 오배자 추출물을 함유하는 테스토스테론 5알파-리덕타아제저해제
JPS617206A (ja) 細胞賦活剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN JP MX US AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase